Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.

Ashley Lora joined an eczema clinical trial for DUPIXENT and paved the way for other Black women to try clinical trials.

Apogee conducted third-party quantitative market research in April 2025 and asked US patients and physicians the likelihood that they would switch to APG777 from their current or previous biologic ...

Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim ... on track to initiate Phase 1b head-to-head trial vs DUPIXENT in 2025 with readout expected in 2H 2026 Positive interim ...

Eli Lilly and Almirall's Ebglyss (lebrikizumab), an anti-IL-13 antibody for atopic dermatitis that offers less frequent dosing than its two predecessors in the class, Sanofi/Regeneron's Dupixent ...

Researchers reported key differences in atopic dermatitis presentation across racial groups and steps clinicians can take to ...

Atopic dermatitis, the most common form of eczema, can lead to dry, itchy, and inflamed skin. It often comes and goes in flares. Atopic dermatitis affects people of all skin tones, but it doesn't ...

A new study conducted by researchers at National Jewish Health has found that early changes in the cheek skin barrier may ...

The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by ...